As outlined here, many reports have identified TIM-3 as an important inhibitory receptor in the glioma/glioblastoma setting, although much remains to be elucidated regarding its signaling and regulatory networks that mechanistically control and dampen immune cell activity in glioblastoma. Here, HAVCR2 is linked to glioma.